CIRCULATING TUMOUR DNA AS A PERSONALISED BIOMARKER IN BREAST CANCER
Grant number: ECF-14-027 | Funding period: 2014 - 2018
Related publications (11)
The value of cell-free DNA for molecular pathology
Caitlin M Stewart, Prachi D Kothari, Florent Mouliere, Richard Mair, Saira Somnay, Ryma Benayed, Ahmet Zehir, Britta Weigelt, Sarah-Jane Dawson, Maria E Arcila, Michael F Berger, Dana WY Tsui
Over the past decade, advances in molecular biology and genomics techniques have revolutionized the diagnosis and treatment of can..
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
Elizabeth L Christie, Sian Fereday, Ken Doig, Swetansu Pattnaik, Sarah-Jane Dawson, David DL Bowtell
Purpose Germline BRCA1 or BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are associated with favorable r..
Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes
Paul Yeh, Michael Dickinson, Sarah Ftouni, Tane Hunter, Devbarna Sinha, Stephen Q Wong, Rishu Agarwal, Ravikiran Vedururu, Kenneth Doig, Chun Yew Fong, Piers Blombery, David Westerman, Mark A Dawson, Sarah-Jane Dawson
The diagnosis and monitoring of myelodysplastic syndromes (MDSs) are highly reliant on bone marrow morphology, which is associated..
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
Paul Yeh, Tane Hunter, Devbarna Sinha, Sarah Ftouni, Elise Wallach, Damian Jiang, Yih-Chih Chan, Stephen Q Wong, Maria Joao Silva, Ravikiran Vedururu, Kenneth Doig, Enid Lam, Gisela Mir Arnau, Timothy Semple, Meaghan Wall, Andjelija Zivanovic, Rishu Agarwal, Pasquale Petrone, Kate Jones, David Westerman
Several novel therapeutics are poised to change the natural history of chronic lymphocytic leukaemia (CLL) and the increasing use ..
The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE"
Peter Savas, Zhi Ling Teo, Christophe Lefevre, Christoffer Flensburg, Franco Caramia, Kathryn Alsop, Mariam Mansour, Prudence A Francis, Heather A Thorne, Maria Joao Silva, Nnennaya Kanu, Michelle Dietzen, Andrew Rowan, Maik Kschischo, Stephen Fox, David D Bowtell, Sarah-Jane Dawson, Terence P Speed, Charles Swanton, Sherene Loi
BACKGROUND: Understanding the cancer genome is seen as a key step in improving outcomes for cancer patients. Genomic assays are em..
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira, Suet-Feung Chin, Oscar M Rueda, Hans-Kristian Moen Vollan, Elena Provenzano, Helen A Bardwell, Michelle Pugh, Linda Jones, Roslin Russell, Stephen-John Sammut, Dana WY Tsui, Bin Liu, Sarah-Jane Dawson, Jean Abraham, Helen Northen, John F Peden, Abhik Mukherjee, Gulisa Turashvili, Andrew R Green, Steve McKinney
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are important challenges in treating ..